# Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advice</td>
<td>3</td>
</tr>
<tr>
<td>Background</td>
<td>4</td>
</tr>
<tr>
<td>Information</td>
<td>5</td>
</tr>
</tbody>
</table>
Advice

NICE is unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was received from Gilead for the technology.
Background

Gilead was invited to submit evidence for this single technology appraisal for tenofovir alafenamide in May 2016.

Gilead has advised NICE that the particular population that would have the greatest need for tenofovir alafenamide cannot be differentiated from the broader population without additional data. Gilead therefore did not make a submission to NICE.

NICE has therefore terminated this single technology appraisal.
Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of tenofovir alafenamide for treating chronic hepatitis B. If, after doing this, organisations still wish to consider tenofovir alafenamide for treating chronic hepatitis B, they should follow the advice on rational local decision-making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.


Accreditation

NICE accredited
www.nice.org.uk/accreditation